1 – 100 of 103
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Baseline Serum Prostate-specific Antigen Value Predicts the Risk of Subsequent Prostate Cancer Death-Results from the Norwegian Prostate Cancer Consortium
(
- Contribution to journal › Article
-
Mark
Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial
2024) In European Urology(
- Contribution to journal › Article
-
Mark
European Association of Nuclear Medicine Focus 5 : Consensus on Molecular Imaging and Theranostics in Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management : A PIONEER Analysis Based on Big Data
(
- Contribution to journal › Article
- 2023
-
Mark
Smoking and Risk of Prostate Cancer and Prostate Cancer Death : A Pooled Study
(
- Contribution to journal › Article
-
Mark
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma : 2023 Update
(
- Contribution to journal › Scientific review
-
Mark
Re: Mark N. Brook, Holly Ní Raghallaigh, Koveela Govindasami, et al. Family History of Prostate Cancer and Survival Outcomes in the UK Genetic Prostate Cancer Study. Eur Urol 2023;83:257-66
(
- Contribution to journal › Letter
-
Mark
The 2022 Updated European Association of Urology Guidelines on the Use of Adjuvant Immune Checkpoint Inhibitor Therapy for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
Re : Laura S. Mertens, Richard P. Meijer, J. Alfred Witjes. Positron Emission Tomography/Computed Tomography for Staging of Bladder Cancer: A Continuing Clinical Controversy. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.09.017
(
- Contribution to journal › Letter
-
Mark
European Association of Urology Guidelines Panel on Renal Cell Carcinoma Update on the New World Health Organization Classification of Kidney Tumours 2022 : The Urologist's Point of View
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Young Age on Starting Prostate-specific Antigen Testing Is Associated with a Greater Reduction in Prostate Cancer Mortality : 24-Year Follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial
(
- Contribution to journal › Article
-
Mark
Long-term Risks of Depression and Suicide Among Men with Prostate Cancer : A National Cohort Study
(
- Contribution to journal › Article
-
Mark
Re : Niraparib and Abiraterone Acetate for Metastatic Castration-resistant Prostate Cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
A Renewal of the TNM Staging System for Patients with Renal Cancer To Comply with Current Decision-making : Proposal from the European Association of Urology Guidelines Panel
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Mapping European Association of Urology Guideline Practice Across Europe : An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries
(
- Contribution to journal › Article
-
Mark
Re : Alexander Cox, Niklas Klümper, Johannes Stein, et al. Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic Evolution. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2023.03.020
(
- Contribution to journal › Letter
- 2022
-
Mark
European Association of Urology Guidelines on Renal Cell Carcinoma : The 2022 Update
(
- Contribution to journal › Scientific review
-
Mark
Reply to Joep J. de Jong and Ewan A. Gibb's Letter to the Editor re: Gottfrid Sjödahl, Johan Abrahamsson, Karin Holmsten, et al. Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes. Eur Urol. 2022;81:316-7. Neoadjuvant Chemotherapy Response in Muscle-invasive Bladder Cancer: Differences in Intrinsic Biology or Subtyping Nomenclature?
(
- Contribution to journal › Letter
-
Mark
2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
Reply to Wei Zhang So, Ziting Wang, and Ho Yee Tiong's Letter to the Editor re : Anna Lantz, David Bock, Olof Akre, et al. Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer: 8-Year Follow-up. Eur Urol 2021;80:650–60
(
- Contribution to journal › Letter
-
Mark
Re : Performance of a Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography–derived Risk-stratification Tool for High-risk and Very High-risk Prostate Cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Re: Keisuke Shigeta, Kazuhiro Matsumoto, Koichiro Ogihara, et al. Does Neoadjuvant Chemotherapy Have Therapeutic Benefit for Node-positive Upper Tract Urothelial Carcinoma? Results of a Multi-center Cohort Study. Urol Oncol. In press. https://doi.org/10.1016/j.urolonc.2021.07.029 : A Plea for Uniform Terminology for Patients with Urothelial Carcinoma Treated with Chemotherapy Before Consolidative Surgery with Curative Intent: Induction Versus Neoadjuvant Chemotherapy
(
- Contribution to journal › Letter
-
Mark
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
(
- Contribution to journal › Article
-
Mark
European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)
(
- Contribution to journal › Scientific review
-
Mark
A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome : No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
(
- Contribution to journal › Article
-
Mark
Microdissection Testicular Sperm Extraction Versus Multiple Needle-pass Percutaneous Testicular Sperm Aspiration in Men with Nonobstructive Azoospermia : A Randomized Clinical Trial
(
- Contribution to journal › Article
-
Mark
Reply to Paulius Bosas, Gintaras Zaleskis, and Dainius Characiejus's Letter to the Editor re : Sylvia H.J. Jochems, Josef Fritz, Christel Häggström, Bengt Järvholm, Pär Stattin, Tanja Stocks. Smoking and Risk of Prostate Cancer and Prostate Cancer Death: A Pooled Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.033. Therapeutic Monitoring in Prostate Cancer Should Involve a Cotinine Test in Current Smokers: Smoking Cessation Remains a Cornerstone in Preventive Health Care Overall and for Men with Prostate Cancer
(
- Contribution to journal › Letter
- 2021
-
Mark
IMAGINE—IMpact Assessment of Guidelines Implementation and Education : The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Reply to Amit Bansal, Ruchir Maheshwari, and Anant Kumar's Letter to the Editor re : Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol 2020;78:757–63
(
- Contribution to journal › Letter
-
Mark
Reply to Deepansh Dalela, Isaac Palma-Zamora, and Craig Rogers’ Letter to the Editor re : Fredrick Leidberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol 2020;78:757–63
(
- Contribution to journal › Letter
-
Mark
Re: Short-term Ciprofloxacin Prophylaxis for Prostate Biopsy and Risk of Aortic Aneurysm. Nationwide, Population-based Cohort Study
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibitor–based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Functional and Oncological Outcomes After Open Versus Robot-assisted Laparoscopic Radical Prostatectomy for Localised Prostate Cancer : 8-Year Follow-up
(
- Contribution to journal › Article
-
Mark
Re : Systemic Therapy for Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC): Systematic Review of Published Trials in the Last 5 Years
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
When the Molecular Subtype Is Hidden Behind a Veil of Stroma
(
- Contribution to journal › Debate/Note/Editorial
- 2020
-
Mark
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
(
- Contribution to journal › Article
-
Mark
Reply to Alireza Ghoreifi and Hooman Djaladat's Letter to the Editor re : Fredrik Liedberg, Petter Kollberg, Marie Allerbo, et al. Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh: A Randomised Study. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.033
(
- Contribution to journal › Letter
-
Mark
Preventing Parastomal Hernia After Ileal Conduit by the Use of a Prophylactic Mesh : A Randomised Study
(
- Contribution to journal › Article
-
Mark
Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer : A Step in the Right Direction but Still a Long Way To Go.
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
European Association of Urology Guidelines Office : How We Ensure Transparent Conflict of Interest Disclosure and Management
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Re : Improving Management of Upper Tract Urothelial Carcinoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Re : 17-Gene Genomic Prostate Score Test Results in the Canary Prostate Active Surveillance Study (PASS) Cohort
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Treatment of High-grade Non–muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations : Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial “NIMBUS”
(
- Contribution to journal › Article
-
Mark
Re : A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. In press. http://doi.org/10.1016/j.eururo.2020.06.048
(
- Contribution to journal › Letter
- 2019
-
Mark
European Association of Urology Guidelines on Renal Cell Carcinoma : The 2019 Update
(
- Contribution to journal › Article
-
Mark
Re : Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol 2019;75:423–32
(
- Contribution to journal › Letter
-
Mark
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Intensive Imaging-based Follow-up of Surgically Treated Localised Renal Cell Carcinoma Does Not Improve Post-recurrence Survival : Results from a European Multicentre Database (RECUR)
(
- Contribution to journal › Letter
-
Mark
Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men
(
- Contribution to journal › Article
-
Mark
Systematic Review of Combination Drug Therapy for Non-neurogenic Lower Urinary Tract Symptoms
(
- Contribution to journal › Scientific review
-
Mark
Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants
(
- Contribution to journal › Article
-
Mark
Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer : The European Association of Urology Position in 2019
(
- Contribution to journal › Article
-
Mark
Reasons for Discontinuing Active Surveillance : Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium
(
- Contribution to journal › Article
-
Mark
Interim Results from the IMPACT Study : Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers
(
- Contribution to journal › Article
-
Mark
Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer's Letter to the Editor re : Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. Eur Urol 2018;73:961–7
(
- Contribution to journal › Letter
- 2018
-
Mark
Erectile Function and Oncologic Outcomes Following Open Retropubic and Robot-assisted Radical Prostatectomy : Results from the LAParoscopic Prostatectomy Robot Open Trial
(
- Contribution to journal › Article
-
Mark
Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer : Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial
(
- Contribution to journal › Article
-
Mark
Port-site Metastases After Robot-assisted Radical Cystectomy : Is There a Publication Bias?
(
- Contribution to journal › Letter
-
Mark
Prostate Cancer Death After Radiotherapy or Radical Prostatectomy : A Nationwide Population-based Observational Study
(
- Contribution to journal › Article
-
Mark
Association Between Lead Time and Prostate Cancer Grade : Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening
(
- Contribution to journal › Article
-
Mark
Health Economic Analysis of Open and Robot-assisted Laparoscopic Surgery for Prostate Cancer Within the Prospective Multicentre LAPPRO Trial
(
- Contribution to journal › Article
-
Mark
Re : Tobias Nordström, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Grönberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. Eur Urol 2015;68:139–46
(
- Contribution to journal › Letter
-
Mark
Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival
(
- Contribution to journal › Article
-
Mark
A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition : The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations
(
- Contribution to journal › Letter
-
Mark
Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men
(
- Contribution to journal › Article
-
Mark
Re : Is Preoperative Assessment and Treatment of Asymptomatic Bacteriuria Necessary for Reducing the Risk of Postoperative Symptomatic Urinary Tract Infection After Urologic Surgical Procedures?
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Updated European Association of Urology Guidelines : Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer
(
- Contribution to journal › Article
- 2017
-
Mark
Reply to Glen D. Santok and Koon H. Rha' Letter to the Editor re : Pär Stattin, Fredrik Sandin, Frederik Birkebæk Thomsen, et al. Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer: A Semiecologic, Nationwide, Population-based Study. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2016.0
(
- Contribution to journal › Letter
-
Mark
Sentinel Node Procedure in Prostate Cancer : A Systematic Review to Assess Diagnostic Accuracy
(
- Contribution to journal › Scientific review
-
Mark
Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study
(
- Contribution to journal › Article
-
Mark
Familial Associations Between Prostate Cancer and Other Cancers
(
- Contribution to journal › Article
-
Mark
Quantifying the Transition from Active Surveillance to Watchful Waiting Among Men with Very Low-risk Prostate Cancer
(
- Contribution to journal › Article
-
Mark
Association of Radical Local Treatment with Mortality in Men with Very High-risk Prostate Cancer : A Semiecologic, Nationwide, Population-based Study
(
- Contribution to journal › Article
-
Mark
Mortality Is Linked to Low Serum Testosterone Levels in Younger and Middle-aged Men
(
- Contribution to journal › Letter
-
Mark
Serum Testosterone Levels in Early Prediction of Prostate Cancer Risk
(
- Contribution to journal › Letter
-
Mark
Should we Refrain from Performing Oophorectomy in Conjunction with Radical Cystectomy for Bladder Cancer?
(
- Contribution to journal › Article
-
Mark
Expression of STAT3 in Prostate Cancer Metastases
(
- Contribution to journal › Article
-
Mark
Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer : Extended Analysis of the Phase 3 PREVAIL Study
(
- Contribution to journal › Article
-
Mark
Updated European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma
(
- Contribution to journal › Article
-
Mark
A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma
(
- Contribution to journal › Scientific review
-
Mark
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
(
- Contribution to journal › Article
-
Mark
What are the Benefits and Harms of Ureteroscopy Compared with Shock-wave Lithotripsy in the Treatment of Upper Ureteral Stones? A Systematic Review
(
- Contribution to journal › Scientific review
-
Mark
Gonadotropin-releasing Hormone Agonists, Orchiectomy, and Risk of Cardiovascular Disease : Semi-ecologic, Nationwide, Population-based Study
(
- Contribution to journal › Article
-
Mark
Benefits and Harms of Treatment of Asymptomatic Bacteriuria : A Systematic Review and Meta-analysis by the European Association of Urology Urological Infection Guidelines Panel
2017) In European Urology(
- Contribution to journal › Article
-
Mark
Re: Treatment Duration of Febrile Urinary Tract Infection: A Pragmatic Randomized, Double-blind, Placebo-controlled Non-inferiority Trial in Men and Women
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Tract Sizes in Miniaturized Percutaneous Nephrolithotomy : A Systematic Review from the European Association of Urology Urolithiasis Guidelines Panel
(
- Contribution to journal › Scientific review
-
Mark
Genetic Alterations in the Molecular Subtypes of Bladder Cancer : Illustration in the Cancer Genome Atlas Dataset
(
- Contribution to journal › Scientific review
- 2016
-
Mark
Circulating Tumor Cell Count as an Indicator of Treatment Benefit in Advanced Prostate Cancer
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Making Predictive Biomarkers Readily Available
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Adipose-derived Stem Cells Counteract Urethral Stricture Formation in Rats
(
- Contribution to journal › Article
-
Mark
Re: Risk of malignant melanoma in men with prostate cancer. Nationwide, population-based cohort study
(
- Contribution to journal › Letter
- 2014
-
Mark
Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival
(
- Contribution to journal › Article
-
Mark
It Ain't what you do, it's the way you do it : Five golden rules for transforming prostate-specific antigen screening
(
- Contribution to journal › Article
- 2013
-
Mark
Patterns and predictors of amelioration of genitourinary toxicity after high-dose intensity-modulated radiation therapy for localized prostate cancer : Implications for defining postradiotherapy urinary toxicity
(
- Contribution to journal › Article
-
Mark
Prospective randomized evaluation of risk-adapted prostate-specific antigen screening in young men : The PROBASE trial
(
- Contribution to journal › Article
- 2011
-
Mark
TMPRSS2-ERG Status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate
(
- Contribution to journal › Article